Frontline polatuzumab vedotin for diffuse large B-cell lymphoma: A survey of clinician impressions.
Ajay MajorEdward Robert Scheffer CliffDaniel A ErmannUrshila DuraniDavid A Russler-GermainPublished in: EJHaem (2022)
In the POLARIX trial, pola-R-CHP demonstrated improved progression-free survival (PFS) compared to R-CHOP in untreated intermediate- to high-risk DLBCL. We surveyed practicing clinicians regarding their interpretation of POLARIX, including impressions of efficacy, safety, and cost. Of 174 respondents, most from academic centers (82%) in the United States (57%), 70% stated they would not replace R-CHOP with pola-R-CHP due to insufficient PFS difference, lack of overall survival benefit, and excessive cost. Respondents not recommending pola-R-CHP expressed concerns about financial implications for both society and patients. We observed considerable heterogeneity in both study interpretation and plans for real-world implementation of pola-R-CHP.
Keyphrases
- diffuse large b cell lymphoma
- free survival
- epstein barr virus
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- healthcare
- peritoneal dialysis
- clinical trial
- palliative care
- randomized controlled trial
- study protocol
- phase iii
- quality improvement
- phase ii
- patient reported outcomes
- weight loss
- body mass index